Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:07 PM
Ignite Modification Date: 2025-12-24 @ 4:07 PM
NCT ID: NCT05698966
Eligibility Criteria: Inclusion Criteria:- - Singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation at risk for / high probability of delivery in the late preterm period (34+0-36+5 weeks of gestation). Criteria for determination of late preterm delivery risk: 1. Preterm uterine contractions with intact membranes, and at least 3 cm dilation or 75% cervical effacement 2. Spontaneous rupture of the membranes 3. Expected preterm delivery for any other indication via induction or cesarean between 24 hours to 7 days after the planned randomization, as determined by the obstetric provider. \- Exclusion Criteria: They had already received a full course of betamethasone. * Expected delivery in less than 12 hours, irrespective of cause including: 1)ruptured membranes in the presence of more than 6 contractions per hour or cervical dilation of 3 centimeters or more unless oxytocin was withheld for at least 12 hours (although other induction agents were allowed), 2) chorioamnionitis, 3) cervical dilation of 8 cm or more, and 4) evidence of non-reassuring fetal status requiring immediate delivery. * Prior ACS treatment * Current known or suspected infection ( viral, bacterial or other) * Pre-gestational diabetes mellitus. * Any infection that required antibiotics or hospitalization in the month prior to study allocation - Poor understanding of the inform consent language
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 45 Years
Study: NCT05698966
Study Brief:
Protocol Section: NCT05698966